Compare CANG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANG | BMEA |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | 96 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.5M | 138.1M |
| IPO Year | 2018 | 2021 |
| Metric | CANG | BMEA |
|---|---|---|
| Price | $0.29 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $9.83 |
| AVG Volume (30 Days) | 816.5K | ★ 1.1M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $428.72 | N/A |
| Revenue Next Year | $18.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.87 |
| 52 Week High | $5.75 | $3.07 |
| Indicator | CANG | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 30.73 | 38.35 |
| Support Level | N/A | $1.05 |
| Resistance Level | $0.50 | $1.47 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.93 | 23.68 |
Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The operations are divided into two reportable segments (i) Bitcoin Mining Business and (ii) International Automobile Trading Business. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.